NCT02064491View on ClinicalTrials.gov

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

May 31, 2017

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Erlotinib

DRUG

Chemotherapy

Trial Locations (7)

Unknown

Helsinki University Hospital, Espoo

Helsinki University Hospital, Helsinki

Oulu University Hospital, Oulu

Pori Central Hospital, Pori

Tampere University Hospital, Tampere

Turku University Hopital, Turku

Vaasa Central Hospital, Vaasa

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Finnish Lung Cancer Group

OTHER

NCT02064491 - Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC | Biotech Hunter | Biotech Hunter